We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.44B
AUM Growth
-$102M
Cap. Flow
-$54M
Cap. Flow %
-2.21%
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$45.2M
2
HUM icon
Humana
HUM
+$23.9M
3
LLY icon
Eli Lilly
LLY
+$20.3M
4
ILMN icon
Illumina
ILMN
+$20.1M
5
ABT icon
Abbott
ABT
+$17.5M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$44.1M
2
UNH icon
UnitedHealth
UNH
+$23.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$23.1M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$21.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$21.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Real Estate 1.86%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTX icon
151
Nkarta
NKTX
$154M
$381K 0.02%
28,988
– –
DHC
152
Diversified Healthcare Trust
DHC
$2.13B
$354K 0.01%
357,720
– –
RPTX
153
DELISTED
Repare Therapeutics
RPTX
$354K 0.01%
29,150
– –
DTIL icon
154
Precision BioSciences
DTIL
$182M
$292K 0.01%
7,484
– –
HARP
155
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$252K 0.01%
25,991
– –
BDTX icon
156
Black Diamond Therapeutics
BDTX
$99.7M
$223K 0.01%
131,990
– –
CYH icon
157
Community Health Systems
CYH
$412M
$190K 0.01%
88,335
– –
PRAX icon
158
Praxis Precision Medicines
PRAX
$8.52B
$170K 0.01%
5,000
– –
ORKA
159
Oruka Therapeutics
ORKA
$5.72B
$67K ﹤0.01%
2,705
– –
SPPI
160
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$49K ﹤0.01%
114,670
– –
ENDP
161
DELISTED
Endo International plc
ENDP
$48K ﹤0.01%
494,607
– –
YARW
162
Yarrow Bioscience, Inc. Common Stock
YARW
$22.4M
$30K ﹤0.01%
150
– –
CRBP icon
163
Corbus Pharmaceuticals
CRBP
$165M
$25K ﹤0.01%
5,144
– –
ALR
164
DELISTED
AlerisLife Inc
ALR
$23K ﹤0.01%
24,237
– –
BLCM
165
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$7K ﹤0.01%
6,000
– –
NXGL icon
166
NexGel
NXGL
$3.9M
$6K ﹤0.01%
4,243
– –
AMN icon
167
AMN Healthcare
AMN
$1.28B
– –
-61,201
Closed -$6.71M
AUPH icon
168
Aurinia Pharmaceuticals
AUPH
$1.87B
– –
-162,599
Closed -$1.63M
BDX icon
169
Becton Dickinson
BDX
$46.9B
– –
-73,930
Closed -$18.2M
BPMC
170
DELISTED
Blueprint Medicines
BPMC
– –
-111,118
Closed -$5.61M
COGT icon
171
Cogent Biosciences
COGT
$6.64B
– –
-146,911
Closed -$1.32M
EMBC icon
172
Embecta
EMBC
$221M
– –
-14,786
Closed -$374K
FATE icon
173
Fate Therapeutics
FATE
$291M
– –
-31,652
Closed -$784K
FULC icon
174
Fulcrum Therapeutics
FULC
$283M
– –
-58,537
Closed -$287K
HOLX
175
DELISTED
Hologic
HOLX
– –
-28,347
Closed -$1.96M
4 5 6
7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Tekla Capital Management held 187 positions worth $2.44B, down 4% from $2.54B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q3 2022 filing shows 10 new, 35 increased, 38 reduced and 19 closed positions. Its largest new stake was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M. The largest sale was McKesson, an estimated $44.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2022 buy was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M.
  • Tekla Capital Management added most to Johnson & Johnson in Q3 2022, an estimated $45.2M increase.
  • Tekla Capital Management's biggest Q3 2022 reduction was McKesson, cutting an estimated $44.1M.
  • Tekla Capital Management fully exited Syneos Health, Inc. Class A Common Stock in Q3 2022, selling an estimated $21.7M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.44B portfolio in Q3 2022.
  • Tekla Capital Management opened 10 new positions and closed 19 in Q3 2022.
  • Tekla Capital Management's portfolio value fell 4% quarter-over-quarter to $2.44B.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.